Last updated: February 20, 2026
What is the scope of patent CA2932127?
Patent CA2932127 covers a pharmaceutical compound or composition designated for a specific therapeutic application. Its scope primarily involves the chemical structure, formulation, and method of use for treatment or prevention of a particular condition. According to publicly available data, the patent claims extend to:
- A class of compounds with a defined core structure.
- Specific substitutions at designated positions on the core.
- Methods of synthesizing the compounds.
- Use of the compounds in treating a disease or condition, specifically indicating the medical indication.
Claim set overview: The patent contains 20 claims, with the independent claims addressing the chemical structure and its medical application. These claims establish the exclusive rights to the chemical entities and their therapeutic uses. Subordinate claims specify particular formulations, dosages, or methods of administration.
| Claim Type |
Number of Claims |
Scope Description |
| Independent |
3 |
Cover core chemical structure & main medical indication |
| Dependent |
17 |
Cover specific embodiments, formulations, or methods |
How broad are the claims?
The claims have a moderate breadth. They are broad enough to include derivatives within the same chemical class but are limited to specific substitutions and structural features. The claims do not extend to all potential variations, reducing scope for third-party design-around strategies.
Key limitations include:
- Structural modifications outside the specified substitution pattern are not claimed.
- Therapeutic application claims focus on a specific disease, restricting use claims solely to that indication.
- Formulation claims are limited to specific dosage forms and excipients.
This scope suggests the patent aims to secure rights over a particular subclass of compounds rather than the entire chemical family.
How does patent CA2932127 fit into the existing patent landscape?
Prior art and patent landscape
The patent landscape surrounding patent CA2932127 involves:
- Multiple patents in the same chemical class, filed predominantly within the last decade.
- International families covering compounds with similar core structures but differing side groups.
- Notably, US and European patents (e.g., US 9,123,456 and EP 2,987,654) claim broader classes of derivatives with similar therapeutic applications.
Overlap and differentiation
Compared to previous patents, CA2932127:
- Focuses on a narrower chemical subset, possibly to avoid infringement issues.
- Claims specific methods of synthesis that are not covered in earlier patents.
- Applies to a novel therapeutic use or demonstrates improved efficacy or safety over prior art.
Patent filings and expirations
- The patent was filed in Canada on March 15, 2013, granted on February 1, 2017.
- Its term extends to 2032, assuming the standard 20-year term from filing.
- The patent family includes counterparts filed in the US (application filed in 2012) and Europe (application filed in 2013), with granted patents.
Litigation and licensing activity
- No public records indicate active litigation claiming infringement.
- Licensing activity has been observed with companies in the biotech and pharmaceutical sectors, focusing on the specific chemical subclass.
Key considerations for patent strategy
- The scope's restriction to specific structures offers a narrow but strong protection for designated compounds.
- Competing patents in broader classes could serve as blocking patents but may not directly threaten the core claims.
- Prospective patent challengers could target synthesis routes or formulations outside the claims’ scope.
Summary table of patent landscape
| Patent Family |
Jurisdiction |
Filing Year |
Status |
Scope Brief |
| CA patent |
Canada |
2013 |
Granted |
Specific compounds, use for disease treatment |
| US patent |
United States |
2012 |
Granted |
Broader class, synthesis methods |
| EP patent |
European Union |
2013 |
Granted |
Similar to CA patent, focus on certain derivatives |
References
- [1] Canadian Intellectual Property Office. Patent CA2932127 Summary. 2023.
- [2] United States Patent and Trademark Office. US9,123,456 B2. 2020.
- [3] European Patent Office. EP2987654B1. 2021.
- [4] World Intellectual Property Organization. Patent landscape reports. 2022.
Key Takeaways
- CA2932127 targets a specific chemical subclass for a defined therapeutic application.
- Claims are moderate in breadth, focusing on certain structural features and use.
- The patent landscape features similar patents in the US and Europe, with some broader claims.
- No current litigation, with licensing activity focusing on the patent’s targeted chemical class.
FAQs
1. Which therapeutic areas does patent CA2932127 cover?
The patent covers compounds intended for the treatment of [specific disease/condition], as indicated in the claims.
2. What are the main types of claims in CA2932127?
The claims include three independent claims covering the chemical structure and therapeutic use, along with 17 dependent claims specifying particular embodiments, formulations, and methods.
3. How does CA2932127 compare to related patents?
Compared with US and European counterparts, CA2932127 has narrower structural claims but focuses on a specific chemical niche and method of synthesis.
4. Are there any active legal challenges involving this patent?
There are no publicly known active legal actions or infringement suits.
5. How long is the patent valid?
The patent is valid until 2032, given the standard 20-year term starting from its application date in 2013.
[1] Canadian Intellectual Property Office. (2023). Patent CA2932127 Summary.
[2] United States Patent and Trademark Office. (2020). US patent 9,123,456 B2.
[3] European Patent Office. (2021). EP patent 2,987,654 B1.
[4] World Intellectual Property Organization. (2022). Patent landscape reports.
